TCA
TMO icon

Trifecta Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Trifecta Capital Advisors’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.91M Buy
12,018
+38
+0.3% +$20.6K 0.91% 37
2025
Q4 		$6.94M Buy
11,980
+179
+2% +$101K 1.03% 32
2025
Q3 		$5.72M Sell
11,801
-132
-1% -$61.4K 0.87% 38
2025
Q2 		$4.84M Sell
11,933
-60
-0.5% -$25.1K 0.81% 40
2025
Q1 		$5.97M Sell
11,993
-175
-1% -$94.8K 1.25% 29
2024
Q4 		$6.33M Sell
12,168
-40
-0.3% -$22K 1.25% 26
2024
Q3 		$7.55M Buy
12,208
+97
+0.8% +$57.4K 1.58% 16
2024
Q2 		$6.7M Buy
12,111
+608
+5% +$348K 1.48% 16
2024
Q1 		$6.69M Buy
11,503
+404
+4% +$227K 1.63% 17
2023
Q4 		$5.89M Buy
11,099
+185
+2% +$89.5K 1.63% 15
2023
Q3 		$5.52M Buy
10,914
+281
+3% +$150K 1.78% 14
2023
Q2 		$5.55M Buy
10,633
+365
+4% +$197K 1.78% 14
2023
Q1 		$5.92M Buy
10,268
+258
+3% +$145K 2.08% 13
2022
Q4 		$5.51M Buy
+10,010
New +$5.3M 2.2% 12

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Trifecta Capital Advisors's TMO Position: Q1 2026 in Review

Trifecta Capital Advisors increased its Thermo Fisher Scientific (TMO) stake by 0.32% in Q1 2026, buying an estimated $20.6K and bringing the position to 12,018 shares worth $5.91M. The position accounts for 0.91% of the portfolio, ranked #37.

Trifecta Capital Advisors first reported a position in TMO in Q4 2022 and has held it in 14 quarters since. The position peaked at $7.55M in Q3 2024. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Trifecta Capital Advisors held 12,018 shares of Thermo Fisher Scientific worth $5.91M as of Q1 2026.
  • Trifecta Capital Advisors bought 38 Thermo Fisher Scientific shares in Q1 2026, an estimated $20.6K.
  • Thermo Fisher Scientific made up 0.91% of Trifecta Capital Advisors's portfolio in Q1 2026, its #37 holding.
  • Trifecta Capital Advisors first reported a position in Thermo Fisher Scientific in Q4 2022 and has held it in 14 quarters since.
  • Trifecta Capital Advisors's Thermo Fisher Scientific position peaked at $7.55M in Q3 2024.
  • 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Trifecta Capital Advisors's 13F filing for Q1 2026, filed 1 May 2026.